Posted inBiotechnology
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months…









